癌症研究
癌症免疫疗法
癌症疫苗
免疫疗法
肽
淋巴系统
化学
免疫系统
TLR7型
结合
医学
表位
癌症
树突状细胞
抗原
兴奋剂
癌细胞
CD86
肿瘤微环境
T细胞
先天免疫系统
背向效应
获得性免疫系统
抗原提呈细胞
巨噬细胞
全身给药
佐剂
CD8型
免疫学
黑色素瘤
抗原呈递
渗透(HVAC)
作者
Yang‐Fan Wu,Jingchu Hu,Ye‐Fan Hu,Wen‐Jun Li,Rong Li,Renhao Li,Yuan Yao,Lehan Hu,Xiao‐Lei Wang,Baozhong Zhang,Yicheng Lu,Shing Fung Chow,Canhui Su,Thomas Yau,Clive Yik‐Sham Chung,Jian‐Dong Huang
摘要
ABSTRACT Peptide cancer vaccines often suffer from poor lymphatic drainage, limited antigen‐presenting cell uptake, and weak innate immune activation. To overcome these barriers, we engineered the Self‐Assembling Peptide‐Adjuvant Conjugate (SaPAC) platform, which covalently links neoantigen epitopes to the TLR7 agonist 1V209 through site‐selective lysine conjugation. Synthesized by Fmoc solid‐phase peptide synthesis, SaPAC conjugates self‐assemble into cationic nanoparticles with hydrodynamic diameters of approximately 100–200 nm. Compared with unconjugated self‐assembling peptide nanoparticles mixed with soluble adjuvant, SaPAC nanoparticles enhanced lymphatic drainage and antigen persistence in draining lymph nodes. Mechanistically, SaPAC activated the TLR7‐MyD88 axis, promoted plasmacytoid dendritic cell and macrophage recruitment, drove APC maturation (CD80 + CD86 + ), and enhanced MHC‐I cross‐presentation to amplify antigen‐specific CD8+ T‐cell priming. Therapeutically, SaPAC monotherapy suppressed tumor growth in B16‐OVA melanoma and MB49 bladder carcinoma models by increasing intratumoral infiltration of activated CD8+ T cells and NK cells. In an orthotopic 4T1 triple‐negative breast cancer model, multivalent SaPAC vaccination synergized with anti‐PD‐1 blockade and achieved durable tumor suppression comparable to the Poly(I:C)‐adjuvanted benchmark without detectable systemic toxicity. Collectively, SaPAC represents a chemically defined platform that bridges innate and adaptive anti‐tumor immunity.
科研通智能强力驱动
Strongly Powered by AbleSci AI